Anbio Biotechnology

Anbio Biotechnology provides in vitro diagnostics (IVD) products globally, including in the European Union, Asia Pacific, North America, and South America. The company offers a range of diagnostic solutions such as lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction technologies. Its product portfolio includes SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. Anbio serves over-the-counter, point-of-care testing, and laboratory markets, making diagnostic tools accessible for various healthcare settings.

Anbio Biotechnology is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol NNNN. The company trades in US Dollars (USD), reflecting its listing on a US-based exchange despite being headquartered in Germany. This allows international investors to trade its shares in a major global market.

Anbio Biotechnology operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This classification indicates that the company develops and manufactures medical devices and supplies, particularly diagnostic instruments and test kits used in healthcare settings. Its focus on in vitro diagnostics aligns with the broader medical instruments industry, which includes tools for disease detection and monitoring.

Anbio Biotechnology is headquartered in Frankfurt am Main, Germany, and was incorporated in 2021. The company serves markets across the European Union, Asia Pacific, North America, South America, and globally. Its geographic reach spans multiple continents, with a focus on providing diagnostic solutions to over-the-counter, point-of-care, and laboratory customers worldwide.